Incyte (INCY) Weekend Data Points To $1B Peak Sales For Ruxolitinib - Stifel

June 17, 2019 8:56 AM EDT Send to a Friend
Stifel analyst Stephen Willey reiterated a Hold rating on Incyte (NASDAQ: INCY) but believes the weekend presentation of complete results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login